Literature DB >> 24860124

Evidence-based use of FFP: the influence of a priming strategy without FFP during CPB on postoperative coagulation and recovery in pediatric patients.

X Miao1, J Liu2, M Zhao1, Y Cui1, Z Feng1, J Zhao1, C Long1, S Li3, F Yan4, X Wang3, S Hu3.   

Abstract

OBJECTIVE: Although fresh frozen plasma (FFP) is one of the most commonly used hemostatic agents in clinical specialties today, there is little evidence available supporting its administration. Our present study observed the effects of a priming strategy without FFP during cardiopulmonary bypass (CPB) on postoperative coagulation and clinical recovery in pediatric patients, aiming to supply new evidence for evidence-based use of FFP.
METHOD: Eighty pediatric patients with congenital heart disease undergoing cardiac surgery with CPB were randomized to receive either 10-20 ml/kg 4% succinylated gelatin (Gelofusine, GEL group, n = 40) or 1-2 units FFP (FFP group, n = 40) in the pump prime. Rapid-thromboelastography (r-TEG) and functional fibrinogen level were measured before skin incision and 15 minutes after heparin reversal. We recorded the volume of chest tube drainage, transfusion requirements and the dosage of pharmacological agents. The ventilation time, ICU length of stay and hospitalization time after surgery were also collected.
RESULTS: After heparin neutralization, there were significantly elevated levels of fibrinogen in the FFP group, which were manifested by r-TEG parameters MAf and FLEV. No significant differences were observed between the two groups in postoperative bleeding, transfusion requirements and the usage of pharmacological agents. Recovery time was also comparable between the two groups.
CONCLUSION: In conclusion, prophylactic use of FFP in the priming solution does not provide clinical benefits as presumed. Artificial colloids, such as Gelofusine, can be used safely and effectively as a substitute for FFP in the pump prime. TEG is an effective assessment tool to evaluate postoperative coagulation function in pediatric patients.
© The Author(s) 2014.

Entities:  

Keywords:  blood conservation; cardiopulmonary bypass; coagulation; congenital heart disease; fresh frozen plasma; thromboelastography

Mesh:

Substances:

Year:  2014        PMID: 24860124     DOI: 10.1177/0267659114537328

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  6 in total

1.  No evidence to support a priming strategy with FFP in infants.

Authors:  David Faraoni; Cristel Sanchez Torres
Journal:  Eur J Pediatr       Date:  2014-07-22       Impact factor: 3.183

2.  Reply to "No evidence to support a priming strategy with FFP in infants".

Authors:  Xiaolei Miao; Jinping Liu
Journal:  Eur J Pediatr       Date:  2014-07-18       Impact factor: 3.183

3.  Plasma and Platelet Transfusions Strategies in Neonates and Children Undergoing Cardiac Surgery With Cardiopulmonary Bypass or Neonates and Children Supported by Extracorporeal Membrane Oxygenation: From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.

Authors:  Jill M Cholette; Jennifer A Muszynski; Juan C Ibla; Sitaram Emani; Marie E Steiner; Adam M Vogel; Robert I Parker; Marianne E Nellis; Melania M Bembea
Journal:  Pediatr Crit Care Med       Date:  2022-01-01       Impact factor: 3.971

Review 4.  Mechanical blood trauma in assisted circulation: sublethal RBC damage preceding hemolysis.

Authors:  Salim E Olia; Timothy M Maul; James F Antaki; Marina V Kameneva
Journal:  Int J Artif Organs       Date:  2016-03-30       Impact factor: 1.595

Review 5.  Fresh frozen plasma for cardiovascular surgery.

Authors:  Michael Desborough; Ravinda Sandu; Susan J Brunskill; Carolyn Doree; Marialena Trivella; Alessandro Montedori; Iosief Abraha; Simon Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14

Review 6.  Transfusion in Neonatal Patients: Review of Evidence-Based Guidelines.

Authors:  Patricia E Zerra; Cassandra D Josephson
Journal:  Clin Lab Med       Date:  2020-12-23       Impact factor: 2.172

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.